CPIC: Clinical Pharmacogenetics Implementation Consortium

The Clinical Pharmacogenetics Implementation Consortium (CPIC) was formed in late 2009, as a shared project between PharmGKB and the Pharmacogenomics Research Network. CPIC guidelines are peer-reviewed and published in a leading journal (in partnership with Clinical Pharmacology and Therapeutics) with simultaneous posting to PharmGKB with supplemental information/data and updates. Anyone with clinical interests in pharmacogenetics is eligible for membership. CPIC's goal is to address some of the barriers to implementation of pharmacogenetic tests into clinical practice.

Questions? Send email to cpic@pharmgkb.org.

CPIC Team

Leader
Mary V. Relling, Pharm.D.
St. Jude Children’s Research Hospital, Memphis
Co-Leader
Teri E. Klein, Ph.D.
Stanford University
Coordinator
Kelly Caudle, Pharm.D., Ph.D.
St. Jude Children’s Research Hospital, Memphis

CPIC Steering Committee

Mary V. Relling, Pharm.D.
St. Jude Children’s Research Hospital
Teri E. Klein, Ph.D.
Stanford University
Julie A. Johnson, Pharm.D.
University of Florida
Dan M. Roden, M.D.
Vanderbilt University
Rachel F. Tyndale, Ph.D.
University of Toronto and CAMH


BACKGROUND

One barrier to clinical implementation of pharmacogenetics is the lack of freely available, peer-reviewed, updatable, and detailed gene/drug clinical practice guidelines. CPIC provides guidelines that enable the translation of genetic laboratory test results into actionable prescribing decisions for specific drugs. The guidelines can center on genes (e.g. thiopurine methyltransferase and its implications for thiopurines) or around drugs (e.g. warfarin and CYP2C9 and VKORC1). Priority is given to genotyping tests that are already offered in CLIA-approved clinical settings.

CPIC GUIDELINES

CPIC guidelines are designed to help clinicians understand HOW available genetic test results should be used to optimize drug therapy, rather than WHETHER tests should be ordered. A key assumption underlying the CPIC guidelines is that clinical high-throughput and pre-emptive (pre-prescription) genotyping will become more widespread, and that clinicians will be faced with having patients' genotypes available even if they have not explicitly ordered a test with a specific drug in mind. Each CPIC guideline adheres to a standard format, and includes a standard system for grading levels of evidence linking genotypes to phenotypes, how to assign phenotypes to clinical genotypes, prescribing recommendations based on genotype/phenotype, and a standard system for assigning strength to each prescribing recommendation. The SOP for guideline creation has been published in Current Drug Metabolism: Incorporation of Pharmacogenomics into Routine Clinical Practice: The Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process. The SOP was updated in June 2014: June 2014 CPIC Authorship Update.

CPIC MEMBERSHIP

CPIC RESOURCES